NICE says yes to Novartis’ multiple sclerosis therapy KesimptaNovartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just Share XNICE says yes to Novartis’ multiple sclerosis therapy Kesimptahttps://pharmaphorum.com/news/nice-says-yes-to-novartis-multiple-sclerosis-therapy-kesimpta/
Scotland opens door to Translarna for Duchenne muscular dystrophyA disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland Share XScotland opens door to Translarna for Duchenne muscular dystrophyhttps://pharmaphorum.com/news/scotland-opens-door-to-translarna-for-duchenne-muscular-dystrophy/
NICE backs Sobi’s Kineret for rare inflammatory diseaseThe UK’s cost-effectiveness agency NICE has recommended that Sobi’s Kineret can be used to treat NHS patients with Share XNICE backs Sobi’s Kineret for rare inflammatory diseasehttps://pharmaphorum.com/news/nice-backs-sobis-kineret-for-rare-inflammatory-disease/
Double first for Scotland as it backs Roche’s Rozlytrek, Novartis’ ZolgensmaThe Scottish Medicines Consortium (SMC) has said Roche’s Rozlytrek can be used by NHS Scotland for the treatment Share XDouble first for Scotland as it backs Roche’s Rozlytrek, Novartis’ Zolgensmahttps://pharmaphorum.com/news/double-first-for-scotland-as-it-backs-roches-rozlytrek-novartis-zolgensma/
NICE says no to AZ’s Lynparza for prostate cancerNHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they Share XNICE says no to AZ’s Lynparza for prostate cancerhttps://pharmaphorum.com/news/nice-says-no-to-azs-lynparza-for-prostate-cancer/
NICE backs broad use for Gilead/Galapagos arthritis pill JyselecaPatients with rheumatoid arthritis (RA) in England will be able to get treatment with Gilead Sciences and Galapagos’ Share XNICE backs broad use for Gilead/Galapagos arthritis pill Jyselecahttps://pharmaphorum.com/news/nice-backs-broad-use-for-gilead-galapagos-arthritis-pill-jyseleca/
Scotland backs Roche’s Rozlytrek for ROS1 lung cancerThe Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of Share XScotland backs Roche’s Rozlytrek for ROS1 lung cancerhttps://pharmaphorum.com/news/scotland-backs-roches-rozlytrek-for-ntrk-tumours/
NICE backs AZ’s Forxiga for heart failureJust a few weeks after its EU approval for heart failure, AstraZeneca’s Forxiga has been backed by NICE Share XNICE backs AZ’s Forxiga for heart failurehttps://pharmaphorum.com/news/nice-backs-azs-forxiga-for-heart-failure/
Okra says AI-based drug price predictor is 90% accurateUK artificial intelligence startup Okra Technologies has launched a new software platform that it claims can take the Share XOkra says AI-based drug price predictor is 90% accuratehttps://pharmaphorum.com/news/okra-ai-based-drug-price-predictor-90-accurate/
